Conjugated recombinant proteins as emerging new drugs

Abstract

Conjugation combines protein domains to achieve new functionalities in therapeutic drugs by utilizing their functional and structural versatility creating highly diverse macromolecules. Several human recombinant protein drugs are being used for the treatment of different diseases. However to improve these recombinant protein drugs’ bioavailability and to incorporate different new features in the single-protein drug, sortase-mediated conjugation is a promising technology. The sortase A enzyme from Staphylococcus aureus can link any two proteins if one contains N-terminal triglycine (GGG) motif and second contains C-terminal LPXTG motif. In this new protein recombinant drugs can be developed. It is estimated that in the future, conventional recombinant protein drugs will be modified with the help of conjugation technology, and new recombinant drugs will be available with further enhancement of recombinant drugs business worldwide.